“…Triptolide (TP), a diterpene triepoxide isolated from Tripterygium wilfordii Hook F, has been widely used to treat inflammatory and autoimmune diseases, such as systemic lupus erythematosus and RA, but its severe systemic toxicity, especially hepatotoxicity, nephrotoxicity, and cardiotoxicity, along with poor solubility, results in a narrow therapeutic window and poor bioavailability that limit its clinical application (Shen et al., 2019 ; Song et al., 2020 ; Liaw et al., 2021 ; Liu et al., 2021 ). TP has been demonstrated to exhibit anti-inflammatory and immunosuppressive activities, and TP derivatives have been demonstrated to inhibit the polarization of macrophages into the proinflammatory M1 phenotype (Shen et al., 2019 ; Fu et al., 2020 ; Liaw et al., 2021 ; Liu et al., 2021 ). Folic acid (FA)-modified liposomes (FA-Lips) have been demonstrated to have enhanced targeting efficiency by binding to FR with high affinity (Nogueira et al., 2015 ; Xue et al., 2020 ).…”